CryoLife Announces Release Date and Teleconference Call Details for the Fiscal Year 2001 Revenues and Earnings Results

January 17, 2002 at 9:38 AM EST

ATLANTA, Jan. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced today that year-end and fourth quarter revenues and earnings will be released on January 29, 2002.

The Company also announced that following the release of financial results, a teleconference will be held promptly at 8:00 a.m. Eastern Time, January 29, 2002, hosted by Steven G. Anderson, CryoLife President and Chief Executive Officer.

Individuals interested in listening to the live teleconference may do so by calling 973-872-3462 a few minutes prior to 8:00 a.m. on January 29, 2002. No identification number is required. Those interested in listening to a replay of the teleconference may do so by calling (toll free) 877-519-4471 or 973-341-3080. The identification number for the replay is 3062059. The replay will be available January 29 through February 1, 2002.

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve, the SynerGraft vascular graft, the world's first tissue-engineered heart valve and vascular replacements, and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com

    CONTACT:  D. Ashley Lee
              Vice President, Chief Financial Officer
              (800) 438-8285